FDA Panel OKs Evista for Breast Cancer
Experts Recommend the Osteoporosis Drug for Use in Preventing Breast Cancer
July 24, 2007 -- An expert panel gave its OK for expanded use of the
osteoporosis drug Evista Tuesday, telling the FDA that the drug appears
effective in preventing some breast cancer.
If the agency follows the panel's advice, it would clear the way for the
drug, also called raloxifene, to be legally sold as a cancer prevention agent
to millions of women.
It would also position the drug as an alternative to the anti-estrogen drug
tamoxifen, which has long been used to help fight breast cancer's return. In
1998, the FDA approved tamoxifen for use by women who hadn't had breast cancer
but were at high risk of developing the disease.
Breast cancer is the second leading cause of cancer death among women, and
about 40,500 American women will die from breast cancer in 2007, according to
the American Cancer Society. About 13% of women are estimated to develop breast
cancer in their lifetime, according to the National Cancer Institute.
"Postmenopausal women at high risk for invasive breast cancer, I think
now should have a choice," says George Sledge, MD, a professor of medicine
at Indiana University. Sledge is also a consultant for Eli Lilly & Co, the
maker of Evista.
Experts voted 10-4, with one abstaining, to recommend that Lilly be allowed
to market Evista's ability to cut the likelihood of breast cancer in
postmenopausal women at high risk for tumors. A company study showed that
raloxifene and tamoxifen are equally effective at reducing the risk of cancer
in those women.
"I do believe raloxifene is effective in reducing breast cancer,"
says panelist Otis Brawley, MD, a professor of oncology at Emory University
School of Medicine.
The panel voted 8 to 6, with one abstention, on whether Lilly should be
allowed to promote Evista's possible cancer-fighting abilities to all
postmenopausal women with osteoporosis.
Three studies filed by the company all showed that women who took Evista for
up to five years developed fewer invasive breast cancers than women who took a
placebo. But women who took the drug also had a higher risk of serious blood
clots and fatal stroke.
An FDA analysis of the three studies was inconclusive as to whether Evista's
potential benefits outweighed its risks. Agency officials said they were
troubled because Lilly had not submitted any data showing whether women who
take Evista actually live longer than those who don't.
"It is uncertain if the balance of benefits and risk factors for women
at high risk is favorable because the magnitude of benefits is unknown,"
says Patricia Cortazar, MD, an FDA safety official.
Several breast cancer advocacy groups opposed the approval. Carolina
Hinestrosa, executive vice president of the Breast Cancer Coalition, says the
government should boost efforts to find causes of breast cancer rather than
approving drugs with relatively small benefits.